The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Only just looked in as been out today. Great news. Flipped back through the posts and main points covered. My views align with cooper, re recommend for approval = as near as approval. That means the diagnostic’s, the tolerances, the efficacy etc have all been written up and ready for final eyes before sign off. Even if there was some gap it would be go back and clarify not throw it out and start again so it’s in the bag.
The 300 customers with emphasis on the GP surgeries is interesting. It’s like a sales lead. You already got a good rapport, the customer may want more (testing) or they may not know that they want it. It’s a good hook by the business and should also lead to an increased B2B customer base.
Icing on the cake is the seller. You only get these prices against a stellar. So if you have an investment horizon of more than next weekend you should do well here when the SP plays catch up. Needless to say I added a few here today. Usual caveats.....
Trek
Twix, having looked into this in some depth, it is likely that covid will circulate in the population for ever like the flu.
Covid will act like the flu, indeed it already has, by mutating, from season to season.
Vaccines will be produced annually based on best guess of which will be the most common strains for the upcoming season. There will be an annual covid shot for the vulberable like the flu.
In which case, testing may be required for ever too. Vaccination may also only give 6-12 months protection. Just like having the disease itself.
It is the new normal.
I expect a vaccine to be available this year.
Testing will still be required but will dwindle.
Oxford vaccine seems to be progressing well and 30m doses if successful will be available in UK in Sept. Anyone's guess but it's right we are focused away from covid. I know dome have said vaccine vould be furthet away and it certainly could. I expect with the urgency snd resources that it will surprise on the nearer term rather than later. Aimho
As we salivate over this mornings RNS I would expect us shortly to receive news on opening negotiations within the USA now that countries are opening their borders.
Have a good day.
Yes that is all I would accept just like the market for anything not priced in on hope months ago. CE needs to be delivered not only expected. It was expected before end q1.
I am very positive about ce delivery but clearly it needs to be done and not said it's nearly done. Then we can see what's left and not priced in
P.s.
I am only selling a trading proportion and will continue trading if opps arise. My core holding will await a far higher price where I am on board with all holders
If I say I didn't sell today then I didnt!
Fwiw...Price already falling when I logged in. I have 20p as start to slowly sell so missed it and presented with a falling price I did not want to trade.
It's not announced today. It's still expected prior to end June and hopefully very soon. It is late from first expectations of q1.
Well, I do feel we are late to the testing party on dates given although that's not to say we can't benefit hugely. No news on novacyt after so long is a complete miss.
I sold none today. This news is not enough as the market has demonstrated.
Twix,
the CE has been recommended for approval and is in the final stages of approval. We more or less have announced it today.
The core molecular diagnostics business continues to perform in line with management expectations and remains on track to build on the strong year end performance announced in the trading update for the year ended 31 March 2020. The Company remains confident of receiving CE marking for its Illumina-based IONA® test in the near future and has been informed that the product has now been recommended for approval and is in the final stages of evaluation.
Why still no mention of our partnership or any details on Novacyt?
A bit late yo the testing party for our own test and dates. However clearly good news. Just not the news I am waiting for I.e the overdue ce
Don't also forget.
The rns headline was the km aunch of testing services.
LR probably sees this as the main news. Clinics, corporate, private, public etc.
Irons will already be in fire on this. You don't just expand your lab capabilities on the off chance you might pick up some work.
Expect news on this front in short order.
absolute no brainer and a job well done by LR. We will do very well from this and again, it's only a side note to the BAU.
pacman
Yourgene already has over 300 laboratory customers and a growing global network of distribution channels in place through which to drive sales of the new Clarigene infectious disease portfolio of products. In addition, the test will be run in the Yourgene service laboratory once it is launched as a CE IVD kit.
The clinics that currently use our products, no doubt have been asking us if we provide a covid test. We have no doubt also been asking them if they would want one.
LR has probably seen a massive upsell opportunity here.
He wont of just woke up one day and thought, we will make a covid test. Research and feedback from our current partners will have driven this.
And when the Ygen test is ready, who do you think these clinics will use.
Appreciate there are other strings to the bow here but Covid-19 is hot topic.
I would argue YGEN is at least 2 months behind, the "Research Use Only" is due end of June with CE July?
had hoped for more for a rise
going back to ncyt
France is up at ncyt going to watch to see if sales update there
Notaflipper
Good post and I would rather be here than GDR. GDR was 7p and now £1.45. I think I can see why James is so vociferous. He's worried people might jump ship and come to YGEN for the huge growth.
YGEN has all the growth in front of it and has world class business and products in huge demand and GDR has a test which is priced in now and a bit of a one trick pony.
Or he bough in on the spike to £3 before the done the placing lol
Ygen has all the growth to come is what I would say!
The narrative in the market today is focusing on recovery stocks due to the news over the bank holiday weekend of Europe opening up without the need for quarantine and over here of non-essential shops opening up by mid-July. So if you look at TUI, CINE, AIG, HOME etc they're all up and in a big way. Whether this is the start of a real recovery depends if you believe a second wave and separately a second lock-down will come.
The comparison to GDR is a good one. NCYT is moving away from PCR testing due to supply issues with PCR reagents. AVCT, despite the incredible market capitalisation, would still need CE-IVD accreditation and has no track record in test accuracy compared to PCR testing accuracy. However Genedrive's 96 SARS-CoV-2 Kit is also a PCR assay test with 100% sensitivity and 98.2% specificity.
In terms of missing the boat GDR's test has only received its CE-IVD marking on the 22nd May so YGEN is roughly 1 month behind as GDR will only begin commercial sales in June. Some would point out that with NCYT that YGEN is actually ahead as it is already producing manufacturing components as part of sales. Others would point out that YGEN has already an established distributor network with 300+ labs.
Investors would invest here for everything other than covid. We are already growing like a nuclear mushroom cloud with our core product portfolio. 86%: yoy growth. Oh and making a profit. The rns just confirmed this is continuing as per expectations.
The CE mark is inbound.
If your investing, your investing for that, Covid is a side show at the moment. But with LR at the helm it could be the precursor to a whole new growth area. You wouldn't bet against him.
James,
this company is not about covid 19 and everyone here knows that. It's an addition to the world class products we already offer. If nothing comes of the covid product who cares. We already have a contract with NCYT and we already reported 86% yoy growth with our business as usual products.
Everything at the moment is public sector. That will shift orbit over the coming months to private. Private clinics, large and small businesses will all need and implement testing.
To date, you've had a lot of what we're 2 bit, zero profit companies, Ncyt, gdr, Avacta etc, announce a test and SP has gone wild. None of these have any form of sales infrastructure like we have. We were a £100 million company before this, with global reach, relationships, marketing in place. When all the furore dies down, and the private sector takes over as the main driver of testing for many months and probably years to come, that's when Ygen will come into its own.
Not sure why potentially investors would invest here for a test that is months away from the market, lots of value to be had in companies with a gold standard test already in the market and building business relationships around the world as we speak.
YGEN test has missed the opportunity imo.
All the clinics that currently use yourgene tests for our core business are going to add covid testing. It will become standard practice. They might even inbsistvon covid testing as part of the pregnancy or other testing process.
We already have this relationships around the world. Slow burner, but if they already use yourgene and are happy with them, it's a lot simpler to stick with one supplier.
Maybe a little late but with YGEN you know the kit will have solid foundations within a market that isn't going anywhere anytime soon. As Pacman said, their infrastructure is there and has been tried and tested.
Agreed but it will come and the herd with it.